Why Is Doximity (DOCS) Stock Soaring Today? Revenue Beat and Guidance Raised, Even as EPS Missed

Doximity reported quarterly revenue of $156.6 million, up 7.3% year over year and ahead of analyst estimates, alongside adjusted EBITDA of $74.77 million that beat the $69.59 million consensus estimate by roughly 7.4%. The headline move, though, was guidance: Doximity raised its full-year revenue outlook to a range of $671 million to $681 million, up from its prior $664 million to $676 million range and above the roughly $670.3 million analysts had modeled. For a company whose stock trades heavily on the durability of its growth trajectory, a raised full-year guide delivered alongside a revenue and EBITDA beat is the combination that most directly signals accelerating, not just adequate, momentum.

The one soft spot in the report was profitability per share: non-GAAP earnings per share of $0.29 came in about 4.2% below analyst consensus, even as EBITDA beat comfortably. That combination — EBITDA ahead of estimates, EPS slightly behind — typically reflects factors below the operating line, such as share count, taxes, or non-operating items, rather than a deterioration in the underlying business Doximity's revenue and EBITDA figures were describing.

DOCS jumped roughly 36% in the fifteen minutes after the report. A move of that size on a healthcare software platform stock reflects the market weighting the raised full-year guidance and the EBITDA beat far more heavily than the modest EPS miss — guidance raises are read as management's own view of forward demand, and a company raising its outlook while already beating current-quarter estimates is a stronger signal than either fact in isolation.